Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802360 · ClinicalTrials.gov registry record · Phase 4
MENOPUR® Versus FOLLISTIM®
A Phase 4 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 173
- Enrollment target
NCT00802360 is a Phase 4 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 173 participants.
The verdict
NCT00802360, a Phase 4 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 173 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of highly purified menotropin (Menopur®) with that of follitropin beta (FOLLISTIM®) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles
Interventions
- DRUG Ganirelix
- DRUG Menotropin
- DRUG Progesterone in oil
- DRUG Progestrone vaginal insert
- DRUG follitropin beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802360
The ClinicalTrials.gov registry entry for NCT00802360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ganirelix is the first listed.
NCT00802360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00802360 about?
NCT00802360 is a clinical study titled "MENOPUR® Versus FOLLISTIM®". To compare the efficacy and safety of highly purified menotropin (Menopur®) with that of follitropin beta (FOLLISTIM®) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles
What is the current status of trial NCT00802360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 173 participants. The study started on 2008-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00802360?
The interventions under investigation include: Ganirelix (DRUG), Menotropin (DRUG), Progesterone in oil (DRUG), Progestrone vaginal insert (DRUG), follitropin beta (DRUG).
Who is sponsoring clinical trial NCT00802360?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.